

**RESULTS OF THE VOTES ON THE RESOLUTIONS SUBMITTED
TO THE EXTRAORDINARY SHAREHOLDERS' MEETING
OF 25 SEPTEMBER 2020**

Number of shares comprising the share capital: 15,174,125

Number of shares excluding from the vote: 115,791

Number of shares with voting rights possessed by shareholders represented or having voted by mail: 12,568,545

In accordance with the provisions of article 4 of Order No. 2020-321 of 25 March 2020 adopted under the powers granted by French Emergency Law No. 2020-290 of 23 March 2020 to deal with the Covid-19 epidemic, extended until November 30, 2020 by Decree No. 2020-925 of 29 July 2020 extending the period of application of Order No. 2020-321 of 25 March 2020, of Decree No. 2020-418 of 10 April 2020 and Decree No. 2020-629 of 25 May 2020, the procedures for organising the Extraordinary General Meeting and the participation of shareholders were adapted.

The Extraordinary General Meeting was held in closed session on Friday, 25 September 2020 at 5:30 p.m. at the Company's headquarters and approved the authorization given to the Board of Directors to grant stock options. The results of the votes on the resolutions proposed at this meeting by the Board of Directors were as follows:

| Resolutions | Results of the votes |
|---|--|
| <ul style="list-style-type: none"> ▪ RESOLUTION ONE Authorization given to the Board of Directors to grant stock options | Resolution adopted by: <ul style="list-style-type: none"> - 11,081,339 votes in favour - 1,487,206 votes against - 0 abstention from voting |
| <ul style="list-style-type: none"> ▪ RESOLUTION TWO Powers for formalities | Resolution adopted by: <ul style="list-style-type: none"> - 12,568,120 votes in favour - 425 votes against - 0 abstention from voting |

Financial calendar

- Participation in the MidCap Event in Paris on 19 and 20 October 2020.
- Publication of Q3 2020 sales: 18 November 2020 (after the close of trading)
- Publication of FY 2020 annual sales: 4 February 2021 (after the close of trading).

About Pharmagest Group:

With more than 1,100 employees and “Citizens in the Service of Health and Well-Being”, Pharmagest Group is the leading provider of IT solutions for the healthcare sector in Europe through innovative solutions and services for healthcare professionals guaranteeing the efficiency of the healthcare system and improving the patient care pathway.

As a key contributor to the quality of healthcare and coordination between office-based private practice and hospitals, Pharmagest Group is present in France, Italy, Belgium, Luxembourg and the United Kingdom where it is developing the leading healthcare platform and a single ecosystem for France and Europe bringing the best of technology to the service of people.

Listed on Euronext Paris™ - Compartment B

Indices: CAC® SMALL and CAC® All-Tradable by inclusion

Eligible for the Long-Only Deferred Settlement Service (SRD)

ISIN: FR 0012882389 – Reuters: PHA.PA – Bloomberg: - PMGI FP



PHARMAGEST shares are eligible for French tax-advantaged PEA-PME equity savings accounts

*The Group is included in the **Gaïa-Index 2019** comprised of socially responsible mid-caps and was recently included in the “**European Rising Tech**” label recognising the top-performing SMEs listed on the Euronext markets of Amsterdam, Brussels, Lisbon and Paris.*

For all the latest news go to www.pharmagest.com

Follow Pharmagest on Twitter: [@Pharmagest](https://twitter.com/Pharmagest), [LinkedIn](https://www.linkedin.com/company/pharmagest) and [Facebook](https://www.facebook.com/Pharmagest)

CONTACTS

Analyst and Investor Relations:

Chief Administrative and Financial Officer : Jean-Yves SAMSON

Tel. +33 (0)3 83 15 90 67 – jean-yves.samson@lacooperativewelcoop.com

Media Relations:

FIN'EXTENSO – Isabelle APRILE

Tel. +33 (0)1 39 97 61 22 - i.aprile@finextenso.fr